Cargando…
HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982313/ https://www.ncbi.nlm.nih.gov/pubmed/35384333 http://dx.doi.org/10.1002/ctm2.791 |
| _version_ | 1784681782404186112 |
|---|---|
| author | Chu, Wendi Xu, Hui Wang, Yanfei Xie, Yongle Chen, Yi‐Li Tan, Xiaorong Huang, Chenghao Wang, Guifeng Wang, Qi Luo, Wenxin Xia, Ningshao Geng, Meiyu Xie, Zuoquan Wang, Chunhe |
| author_facet | Chu, Wendi Xu, Hui Wang, Yanfei Xie, Yongle Chen, Yi‐Li Tan, Xiaorong Huang, Chenghao Wang, Guifeng Wang, Qi Luo, Wenxin Xia, Ningshao Geng, Meiyu Xie, Zuoquan Wang, Chunhe |
| author_sort | Chu, Wendi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8982313 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89823132022-04-11 HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities Chu, Wendi Xu, Hui Wang, Yanfei Xie, Yongle Chen, Yi‐Li Tan, Xiaorong Huang, Chenghao Wang, Guifeng Wang, Qi Luo, Wenxin Xia, Ningshao Geng, Meiyu Xie, Zuoquan Wang, Chunhe Clin Transl Med Letter to the Editor John Wiley and Sons Inc. 2022-04-05 /pmc/articles/PMC8982313/ /pubmed/35384333 http://dx.doi.org/10.1002/ctm2.791 Text en © 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor Chu, Wendi Xu, Hui Wang, Yanfei Xie, Yongle Chen, Yi‐Li Tan, Xiaorong Huang, Chenghao Wang, Guifeng Wang, Qi Luo, Wenxin Xia, Ningshao Geng, Meiyu Xie, Zuoquan Wang, Chunhe HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities |
| title | HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities |
| title_full | HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities |
| title_fullStr | HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities |
| title_full_unstemmed | HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities |
| title_short | HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities |
| title_sort | her2/pd1 bispecific antibody in igg4 subclass with superior anti‐tumour activities |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982313/ https://www.ncbi.nlm.nih.gov/pubmed/35384333 http://dx.doi.org/10.1002/ctm2.791 |
| work_keys_str_mv | AT chuwendi her2pd1bispecificantibodyinigg4subclasswithsuperiorantitumouractivities AT xuhui her2pd1bispecificantibodyinigg4subclasswithsuperiorantitumouractivities AT wangyanfei her2pd1bispecificantibodyinigg4subclasswithsuperiorantitumouractivities AT xieyongle her2pd1bispecificantibodyinigg4subclasswithsuperiorantitumouractivities AT chenyili her2pd1bispecificantibodyinigg4subclasswithsuperiorantitumouractivities AT tanxiaorong her2pd1bispecificantibodyinigg4subclasswithsuperiorantitumouractivities AT huangchenghao her2pd1bispecificantibodyinigg4subclasswithsuperiorantitumouractivities AT wangguifeng her2pd1bispecificantibodyinigg4subclasswithsuperiorantitumouractivities AT wangqi her2pd1bispecificantibodyinigg4subclasswithsuperiorantitumouractivities AT luowenxin her2pd1bispecificantibodyinigg4subclasswithsuperiorantitumouractivities AT xianingshao her2pd1bispecificantibodyinigg4subclasswithsuperiorantitumouractivities AT gengmeiyu her2pd1bispecificantibodyinigg4subclasswithsuperiorantitumouractivities AT xiezuoquan her2pd1bispecificantibodyinigg4subclasswithsuperiorantitumouractivities AT wangchunhe her2pd1bispecificantibodyinigg4subclasswithsuperiorantitumouractivities |